The clinical utility of gene testing for Alzheimer... [Neurol Int. 2011] - PubMed result

The clinical utility of gene testing for Alzheimer... [Neurol Int. 2011] - PubMed result: "Neurol Int. 2011 Jun;3(1):e1. Epub 2011 Apr 6.
The clinical utility of gene testing for Alzheimer's disease.
Atkins ER, Panegyres PK.

Source

Neurodegenerative Disorders Research, Subiaco, Australia.

Abstract

Alzheimer's disease (AD) is the largest cause of dementia, affecting 35.6 million people in 2010. Amyloid precursor protein, presenilin 1 and presenilin 2 mutations are known to cause familial early-onset AD, whereas apolipoprotein E (APOE) ε4 is a susceptibility gene for late-onset AD. The genes for phosphatidylinositol-binding clathrin assembly protein, clusterin and complement receptor 1 have recently been described by genome-wide association studies as potential risk factors for late-onset AD. Also, a genome association study using single neucleotide polymorphisms has identified an association of neuronal sortilin related receptor and late-onset AD. Gene testing, and also predictive gene testing, may be of benefit in suspected familial early-onset AD however it adds little to the diagnosis of late-onset AD and does not alter the treatment. We do not recommend APOE ε4 genotyping.

PMID:
21785673
[PubMed - in process]
PMCID: PMC3141112

- Enviado mediante la barra Google"